메뉴 건너뛰기




Volumn 34, Issue 1, 2014, Pages 78-88

Safety and efficacy of faldaprevir with pegylated interferon alfa-2a and ribavirin in Japanese patients with chronic genotype-1 hepatitis C infection

Author keywords

Faldaprevir; Genotype 1; Hepatitis C virus; Japanese

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; FALDAPREVIR; HEMOGLOBIN; PEGINTERFERON ALPHA2A; PLACEBO; RIBAVIRIN;

EID: 84890126935     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12254     Document Type: Article
Times cited : (23)

References (29)
  • 1
    • 84890130134 scopus 로고    scopus 로고
    • World Health Organization. Hepatitis C Fact sheet N°164. Available at Accessed 19 October 2012.
    • World Health Organization. Hepatitis C Fact sheet N°164. 2012 Available at http://www.who.int/mediacentre/factsheets/fs164/en/index.html. Accessed 19 October 2012.
    • (2012)
  • 2
    • 79958717571 scopus 로고    scopus 로고
    • The global health burden of hepatitis C virus infection
    • Negro F, Alberti A. The global health burden of hepatitis C virus infection. Liver Int 2011; 31 (Suppl. 2): 1-3.
    • (2011) Liver Int , vol.31 , Issue.SUPPL. 2 , pp. 1-3
    • Negro, F.1    Alberti, A.2
  • 3
    • 84862929577 scopus 로고    scopus 로고
    • The burden of illness for patients with viral hepatitis C: evidence from a national survey in Japan
    • Liu GG, DiBonaventura M, Yuan Y, et al. The burden of illness for patients with viral hepatitis C: evidence from a national survey in Japan. Value Health 2012; 15: S65-71.
    • (2012) Value Health , vol.15
    • Liu, G.G.1    DiBonaventura, M.2    Yuan, Y.3
  • 4
    • 79959722134 scopus 로고    scopus 로고
    • All-cause, liver-related, and non-liver-related mortality among HCV-infected individuals in the general US population
    • El-Kamary SS, Jhaveri R, Shardell MD. All-cause, liver-related, and non-liver-related mortality among HCV-infected individuals in the general US population. Clin Infect Dis 2011; 53: 150-7.
    • (2011) Clin Infect Dis , vol.53 , pp. 150-157
    • El-Kamary, S.S.1    Jhaveri, R.2    Shardell, M.D.3
  • 5
    • 79954708052 scopus 로고    scopus 로고
    • Trends in mortality after diagnosis of hepatitis B or C infection: 1992-2006
    • Walter SR, Thein HH, Amin J, et al. Trends in mortality after diagnosis of hepatitis B or C infection: 1992-2006. J Hepatol 2011; 54: 879-86.
    • (2011) J Hepatol , vol.54 , pp. 879-886
    • Walter, S.R.1    Thein, H.H.2    Amin, J.3
  • 6
    • 84856036274 scopus 로고    scopus 로고
    • Advanced liver disease: what every hepatitis C virus treater should know
    • Sherman KE. Advanced liver disease: what every hepatitis C virus treater should know. Top Antivir Med 2011; 19: 121-5.
    • (2011) Top Antivir Med , vol.19 , pp. 121-125
    • Sherman, K.E.1
  • 7
    • 81855206319 scopus 로고    scopus 로고
    • Risk factors for hepatocellular carcinoma in a cohort infected with hepatitis B or C
    • Walter SR, Thein HH, Gidding HF, et al. Risk factors for hepatocellular carcinoma in a cohort infected with hepatitis B or C. J Gastroenterol Hepatol 2011; 26: 1757-64.
    • (2011) J Gastroenterol Hepatol , vol.26 , pp. 1757-1764
    • Walter, S.R.1    Thein, H.H.2    Gidding, H.F.3
  • 10
    • 24944439884 scopus 로고    scopus 로고
    • National prevention of hepatocellular carcinoma in Japan based on epidemiology of hepatitis C virus infection in the general population
    • Yoshizawa H, Tanaka J, Miyakawa Y. National prevention of hepatocellular carcinoma in Japan based on epidemiology of hepatitis C virus infection in the general population. Intervirology 2006; 49: 7-17.
    • (2006) Intervirology , vol.49 , pp. 7-17
    • Yoshizawa, H.1    Tanaka, J.2    Miyakawa, Y.3
  • 11
    • 75349095780 scopus 로고    scopus 로고
    • Changing trends in hepatitis C infection over the past 50 years in Japan
    • Chung H, Ueda T, Kudo M. Changing trends in hepatitis C infection over the past 50 years in Japan. Intervirology 2010; 53: 39-43.
    • (2010) Intervirology , vol.53 , pp. 39-43
    • Chung, H.1    Ueda, T.2    Kudo, M.3
  • 12
    • 84860287080 scopus 로고    scopus 로고
    • Epidemiology of viral hepatitis and hepatocellular carcinoma
    • El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012; 142: 1264-73.
    • (2012) Gastroenterology , vol.142 , pp. 1264-1273
    • El-Serag, H.B.1
  • 13
    • 84883897873 scopus 로고    scopus 로고
    • Japan Society of Hepatology. Treatment guidelines for chronic hepatitis C.
    • Japan Society of Hepatology. Treatment guidelines for chronic hepatitis C. Hep Research 2013; 43: 1-34.
    • (2013) Hep Research , vol.43 , pp. 1-34
  • 14
    • 83555163652 scopus 로고    scopus 로고
    • Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan
    • Kumada H, Toyota J, Okanoue T, et al. Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan. J Hepatol 2012; 56: 78-84.
    • (2012) J Hepatol , vol.56 , pp. 78-84
    • Kumada, H.1    Toyota, J.2    Okanoue, T.3
  • 15
    • 84890114466 scopus 로고    scopus 로고
    • Telaprevir in combination with peginterferon alfa 2B and ribavirin therapy for genotype 1 chronic HCV patients: phase 3 study in Japan
    • Abstract No. 1330].
    • Okanoue T, Hayashi N, Tsubouchi H, et al. Telaprevir in combination with peginterferon alfa 2B and ribavirin therapy for genotype 1 chronic HCV patients: phase 3 study in Japan. Hepatology 2011; 54(Suppl. 1): 985A [Abstract No. 1330].
    • (2011) Hepatology , vol.54 , Issue.SUPPL. 1
    • Okanoue, T.1    Hayashi, N.2    Tsubouchi, H.3
  • 16
    • 79959438789 scopus 로고    scopus 로고
    • Telaprevir for previously untreated chronic hepatitis C virus infection
    • Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-16.
    • (2011) N Engl J Med , vol.364 , pp. 2405-2416
    • Jacobson, I.M.1    McHutchison, J.G.2    Dusheiko, G.3
  • 17
    • 79959381354 scopus 로고    scopus 로고
    • Telaprevir for retreatment of HCV infection
    • Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417-28.
    • (2011) N Engl J Med , vol.364 , pp. 2417-2428
    • Zeuzem, S.1    Andreone, P.2    Pol, S.3
  • 18
    • 79960328806 scopus 로고    scopus 로고
    • Antiviral effects of peginterferon alpha-2b and ribavirin following 24-week monotherapy of telaprevir in Japanese hepatitis C patients
    • Ozeki I, Akaike J, Karino Y, et al. Antiviral effects of peginterferon alpha-2b and ribavirin following 24-week monotherapy of telaprevir in Japanese hepatitis C patients. J Gastroenterol 2011; 46: 929-37.
    • (2011) J Gastroenterol , vol.46 , pp. 929-937
    • Ozeki, I.1    Akaike, J.2    Karino, Y.3
  • 19
    • 84890115803 scopus 로고    scopus 로고
    • INCIVEK™ (telaprevir) Highlights of US prescribing information. Accessed 21 February 2012.
    • INCIVEK™ (telaprevir) Highlights of US prescribing information. 2011 Available at http://pi.vrtx.com/files/uspi_telaprevir.pdf. Accessed 21 February 2012.
    • (2011)
  • 20
    • 84890118946 scopus 로고    scopus 로고
    • INCIVO™ (telaprevir) Summary of product characteristics. Available at Accessed 19 October 2012.
    • INCIVO™ (telaprevir) Summary of product characteristics. 2011 Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002313/WC500115529.pdf. Accessed 19 October 2012.
    • (2011)
  • 21
    • 80054908770 scopus 로고    scopus 로고
    • Directly acting antivirals for hepatitis C and antiretrovirals: potential for drug-drug interactions
    • Seden K, Back D. Directly acting antivirals for hepatitis C and antiretrovirals: potential for drug-drug interactions. Curr Opin HIV AIDS 2011; 6: 514-26.
    • (2011) Curr Opin HIV AIDS , vol.6 , pp. 514-526
    • Seden, K.1    Back, D.2
  • 22
    • 77956301340 scopus 로고    scopus 로고
    • Discovery of a potent and selective noncovalent linear inhibitor of the hepatitis C virus NS3 protease (BI 201335)
    • Llinas-Brunet M, Bailey MD, Goudreau N, et al. Discovery of a potent and selective noncovalent linear inhibitor of the hepatitis C virus NS3 protease (BI 201335). J Med Chem 2010; 53: 6466-76.
    • (2010) J Med Chem , vol.53 , pp. 6466-6476
    • Llinas-Brunet, M.1    Bailey, M.D.2    Goudreau, N.3
  • 23
    • 79953224799 scopus 로고    scopus 로고
    • Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection
    • Manns MP, Bourliere M, Benhamou Y, et al. Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection. J Hepatol 2011; 54: 1114-22.
    • (2011) J Hepatol , vol.54 , pp. 1114-1122
    • Manns, M.P.1    Bourliere, M.2    Benhamou, Y.3
  • 24
    • 78049316315 scopus 로고    scopus 로고
    • Preclinical characterization of BI 201335, a C-terminal carboxylic acid inhibitor of the hepatitis C virus NS3-NS4A protease
    • White PW, Llinas-Brunet M, Amad M, et al. Preclinical characterization of BI 201335, a C-terminal carboxylic acid inhibitor of the hepatitis C virus NS3-NS4A protease. Antimicrob Agents Chemother 2010; 54: 4611-8.
    • (2010) Antimicrob Agents Chemother , vol.54 , pp. 4611-4618
    • White, P.W.1    Llinas-Brunet, M.2    Amad, M.3
  • 25
    • 84878992253 scopus 로고    scopus 로고
    • Faldaprevir combined with peginterferon alfa-2a and ribavirin in treatment-naive patients with chronic genotype-1 HCV: SILEN-C1 trial
    • Sulkowski MS, Asselah T, Lalezari J, et al. Faldaprevir combined with peginterferon alfa-2a and ribavirin in treatment-naive patients with chronic genotype-1 HCV: SILEN-C1 trial. Hepatology 2013; 57: 2143-54.
    • (2013) Hepatology , vol.57 , pp. 2143-2154
    • Sulkowski, M.S.1    Asselah, T.2    Lalezari, J.3
  • 26
    • 84878980518 scopus 로고    scopus 로고
    • Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic HCV genotype-1 patients with prior nonresponse: SILEN-C2 trial
    • Sulkowski MS, Bourliere M, Bronowicki JP, et al. Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic HCV genotype-1 patients with prior nonresponse: SILEN-C2 trial. Hepatology 2013; 57: 2155-63.
    • (2013) Hepatology , vol.57 , pp. 2155-2163
    • Sulkowski, M.S.1    Bourliere, M.2    Bronowicki, J.P.3
  • 27
    • 4043117056 scopus 로고
    • Design of first-administration studies in healthy man
    • In: O'Grady J, Linet OI (eds), London: MacMillan Press
    • Broom C. Design of first-administration studies in healthy man. In: O'Grady J, Linet OI (eds), Early Phase Drug Evaluation in Man, London: MacMillan Press; 1990. p206-13.
    • (1990) Early Phase Drug Evaluation in Man
    • Broom, C.1
  • 28
    • 80054891773 scopus 로고    scopus 로고
    • Mechanisms of isolated unconjugated hyperbilirubinemia induced by the HCV NS3/4A protease inhibitor BI201335
    • Abstract No. 1236].
    • Sane R, Podila L, Mathur A, et al. Mechanisms of isolated unconjugated hyperbilirubinemia induced by the HCV NS3/4A protease inhibitor BI201335. J Hepatol 2011; 54 (Suppl. 1): S488 [Abstract No. 1236].
    • (2011) J Hepatol , vol.54 , Issue.SUPPL. 1
    • Sane, R.1    Podila, L.2    Mathur, A.3
  • 29
    • 79960470493 scopus 로고    scopus 로고
    • SILEN-C3: treatment for 12 or 24 weeks with BI201335 combined with peginterferon alfa-2A and ribavirin (P.R) in treatment-naive patients with chronic genotype-1 HCV infection
    • Abstract No. 36].
    • Dieterich D, Asselah T, Guyader D, et al. SILEN-C3: treatment for 12 or 24 weeks with BI201335 combined with peginterferon alfa-2A and ribavirin (P.R) in treatment-naive patients with chronic genotype-1 HCV infection. Hepatology 2011; 54 (Suppl.): 378A [Abstract No. 36].
    • (2011) Hepatology , vol.54 , Issue.SUPPL.
    • Dieterich, D.1    Asselah, T.2    Guyader, D.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.